INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2016

Adding extended-release niacin with laropiprant to statin therapy reduced quality-adjusted life years and increased hospital costs over 4 years.

In the HPS2-THRIVE trial, 25,673 participants aged 50 to 80 years with prior cardiovascular disease receiving statin therapy were randomized to 2 g extended-release niacin with 40 mg laropiprant daily or placebo for 4 years. Participants assigned to niacin-laropiprant experienced non-significantly lower survival (0.012 fewer years [SE 0.007]), significantly fewer quality-adjusted life years (0.023 [SE 0.007] fewer using UK EQ-5D; 0.020 [SE 0.006] fewer using US EQ-5D), and higher hospital costs (UK £101 [SE £37]; US $145 [SE $53]). Stroke, heart failure, musculoskeletal, gastrointestinal, and infection events were associated with substantial declines in quality of life and increased hospital costs.

Study type
Randomized controlled trial
Who was studied
25,673 participants aged 50 to 80 years with previous cardiovascular disease
What was measured
Quality-adjusted life years, survival, and hospital care costs

THE PAPER

Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.

Kent S, Haynes R, Hopewell JC, Parish S, Gray A, Landray MJ, Collins R, Armitage J, Mihaylova B, HPS2-THRIVE Collaborative Group. Circ Cardiovasc Qual Outcomes, 2016.

PubMed 27407053 ↗DOI 10.1161/circoutcomes.115.002592 ↗

Heart & arteriesNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.